For the majority of the compared values, a GS of 4° showed a trend toward comparable or increased target coverage (D 95% ) and CI, reduced tail doses (D2%), and increased HI, compared with a GS of 2° or 3°.
← all excerpts
Validation of the relative insensitivity of volumetric-modulated arc therapy (VMAT) plan quality to gantry space resolution.
1
—
—